Financial 15 Split Corp. Announces Overnight Offering

TORONTO, ONTARIO -- (Marketwired) -- 11/17/16 -- Financial 15 Split Corp. (the "Company") is pleased to announce it has filed a preliminary short form prospectus in each of the provinces of Canada with respect to an offering of Preferred Shares and Class A Shares of the Company. The offering will be co-led by National Bank Financial Inc., CIBC, RBC Capital Markets, Scotia Capital Inc., and will also include BMO Capital Markets, GMP Securities L.P., Canaccord Genuity Corp., Raymond James, Desjardins Securities Inc., Mackie Research Capital Corporation and Manulife Securities Incorporated.

The Preferred Shares will be offered at a price of $10.00 per Preferred Share to yield 5.25% and the Class A Shares will be offered at a price of $8.75 per Class A Share to yield 17.24%. The closing price on the TSX of each of the Preferred Shares and the Class A Shares on November 16, 2016 was $10.15 and $9.02, respectively.

Since inception of the Company, the aggregate dividends paid on the Preferred Shares have been $6.81 per share and the aggregate dividends paid on the Class A Shares have been $15.63 per share, for a combined total of $22.44. All distributions to date have been made in tax advantage eligible Canadian dividends or capital gains dividends.

The net proceeds of the offering will be used by the Company to invest in an actively managed, high quality portfolio consisting of 15 financial services companies made up of Canadian and U.S. issuers as follows:

Bank of Montreal         National Bank of Canada   Bank of America Corp.
The Bank of Nova Scotia  Manulife Financial        Citigroup Inc.
                         Corporation
Canadian Imperial Bank   Sun Life Financial        Goldman Sachs Group Inc.
 of Commerce             Services of Canada Inc.
Royal Bank of Canada     Great-West Lifeco Inc.    JP Morgan Chase & Co.
The Toronto-Dominion     CI Financial Corp.        Wells Fargo & Co.
 Bank

The Company's investment objectives are:

Preferred Shares:

i.  to provide holders of the Preferred Shares with fixed, cumulative
    preferential monthly cash dividends currently in the amount of 5.25%
    annually, to be set by the Board of Directors annually subject to a
    minimum of 5.25% until 2020; and
ii. on or about the termination date, currently December 1, 2020 (subject to
    further 5 year extensions thereafter), to pay the holders of the
    Preferred Shares $10.00 per Preferred Share.

Class A Shares:

i.  to provide holders of the Class A Shares with regular monthly cash
    dividends in an amount to be determined by the Board of the Directors;
    and
ii. to permit holders to participate in all growth in the net asset value of
    the Company above $10 per Unit, by paying holders on or about the
    termination date of December 1, 2020 (subject to further 5 year
    extensions thereafter) such amounts as remain in the Company after
    paying $10 per Preferred Share.

The sales period of this overnight offering will end at 9:00 a.m. EST on November 18, 2016.

A preliminary short form prospectus containing important information relating to the Preferred Shares and the Class A Shares has been filed with securities commissions or similar authorities in all provinces of Canada. The preliminary short form prospectus is still subject to completion or amendment. Copies of the preliminary short form prospectus may be obtained from your registered financial advisor using the contact information for such advisor, or from representatives of the underwriters listed above. There will not be any sale or any acceptance of an offer to buy the Preferred Shares or the Class A Shares until a receipt for the final short form prospectus has been issued.

Contacts:
Financial 15 Split Corp.
Investor Relations
416-304-4443
Toll free at 1-877-4-Quadra
www.financial15.com

Source: Financial 15 Split Corp.

You May Also Be Interested In

• Financial 15 Split Corp. Monthly Dividend Declaration for Class A & Preferred Share
• 1899, LLC, Awarded Concessions Contract for 2024 Summer Season at Easton's Beach
• ASCO 2024 | Ascentage Pharma to Present Four Studies, Including an Oral Report Featuring the Latest Data of Olverembatinib in SDH-Deficient GIST